$AGTC News

Last published 3y ago

3y agoAGTCSyncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies CorporationGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today the successful completion of the previously
3y agoAGTCSyncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies CorporationGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), announced today that a portfolio company of Syncona Limited
3y agoAGTC*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*GlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona
3y agoAGTC*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*GlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A
3y agoAGTCApplied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022GlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), President and Chief Executive Officer, Sue Washer, sent the following letter to
4y agoAGTCApplied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022GlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), President and Chief Executive Officer, Sue Washer, sent the following letter to
4y agoAGTCSyncona Commences Tender Offer for All Outstanding Shares of Applied Genetic Technologies CorporationGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass. and LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC) ("AGTC" or the "Company") and a newly established portfolio company of Syncona
4y agoAGTCSyncona to Acquire Applied Genetic Technologies CorporationGlobeNewswireUpfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC's closing stock price on October 21, 2022 Total consideration of up to $1.07, including up to $0.73 per CVR,
4y agoAGTCAGTC to Participate in Upcoming Investor ConferencesGlobeNewswireGAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the development and potential commercializat
4y agoAGTCAGTC to Participate in Upcoming Investor ConferencesGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the development and potential commercializatio
4y agoAGTCAGTC Receives Positive Type C Meeting Feedback from the FDA for the Company's Design and Operating Procedures of its Planned cGMP Manufacturing FacilityGlobeNewswire— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC's pipeline, including the late-stage development and potential commercialization of AGTC's X-Linked Retinitis Pigmentosa (XLRP) and Achromatopsia B3 (ACHM
4y agoAGTCAGTC Announces Pricing of $10 Million Underwritten Public OfferingGlobeNewswireGAINESVILLE, Fla., and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the development and commercialization of aden
4y agoAGTCAGTC Announces Proposed Underwritten Public OfferingGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation ("AGTC" or the "Company") (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno
4y agoAGTCAGTC to Present at Upcoming American Society of Retina Specialists Annual MeetingGlobeNewswireGAINESVILLE, Fla., and CAMBRIDGE, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies
4y agoAGTC OCULAurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical OfficerBusiness WireLeading Ophthalmologist and Experienced Industry Executive to Advance Development of Innovative Corneal Endothelial Cell Therapy Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies,
4y agoAGTCAGTC Announces Key Appointments to Leadership TeamGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies fo
4y agoAGTCAGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual MeetingGlobeNewswireGAINESVILLE, Fla., and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies
4y agoAGTCAGTC Announces Age-Related Macular Degeneration Scientific Advisory BoardGlobeNewswireGAINESVILLE, Fla., and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies
4y agoAGTCAGTC to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for
4y agoAGTCAGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis PigmentosaGlobeNewswire– 62.5% of Patients in Dose Group B Were Responders for Improvements in Visual Sensitivity, the Study's Primary Efficacy Endpoint – – Continued Strong Safety Data – – Robust Safety and Efficacy Data Consistent with Previously Reported Res
4y agoAGTCAGTC Hosts Topping Off Ceremony for Gene Therapy Manufacturing Facility to Celebrate the Building's Structural CompletionGlobeNewswire– Facility in Alachua, Florida Is Expected to be Completed in the Fourth Quarter of 2022 – GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotec
4y agoAGTCPositive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual MeetingGlobeNewswire– Data reconfirm previously highlighted safety and efficacy potential of AGTC-501 as a treatment for X-linked retinitis pigmentosa (XLRP) – GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technolo
4y agoAGTCAGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell TherapyGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies fo
4y agoAGTCAGTC to Present at Cell & Gene Meeting on the MediterraneanGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies fo
4y agoAGTCAGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual MeetingGlobeNewswireGAINESVILLE, Fla., and CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies
4y agoAGTCAGTC Announces Pricing of Public Offering of Common StockGlobeNewswireGAINESVILLE, Fla., and CAMBRIDGE, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-
4y agoAGTCAGTC Announces Proposed Public Offering of Common StockGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical-stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-b
4y agoAGTCAGTC to Participate in Upcoming Investor ConferencesGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-
4y agoAGTCAGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2021GlobeNewswire-Company on track to provide 3-month interim SKYLINE trial results in 2Q 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Techn
4y agoAGTCAGTC Announces Robust Improvements in Visual Sensitivity in Adult and Pediatric Patients, and Plans to Continue Clinical Development of AGTC-401 in Patients with CNGB3 AchromatopsiaGlobeNewswireAGTC-401 demonstrated a favorable safety profile through second-highest dose (1.1E+12 vg/mL) in ACHMB3 pediatric patients At the dose of 1.1E+12 vg/mL greater than 50% of the combined adults and children that received AGTC-401 were responders based on
4y agoAGTCAGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022GlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-ba
4y agoAGTCAGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)GlobeNewswireCompany on track to report three-month interim study results, including visual acuity, visual sensitivity, mobility and safety data, in Q2 2022 Company providing further updated guidance on other milestones GAINESVILLE, Fla. and CAMBRIDGE, Mass.
4y agoAGTCAGTC to Participate in the H.C. Wainwright BioConnect 2022 ConferenceGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-ba
4y agoAGTCAGTC Appoints Biopharmaceutical Industry Leader James Robinson to its Board of DirectorsGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a clinical stage biotechnology company focused on the development and commercialization of adeno-associated virus (AAV)-b
4y agoAGTCAGTC Appoints Abraham Scaria, Ph.D., as Chief Science OfficerGlobeNewswireWith 25+ years of experience, Dr. Scaria has led numerous gene therapy programs from early research into clinical development Dr. Scaria completes a newly expanded management team in place to continue development of late-stage programs in XLRP and Ac
5y agoAGTCAGTC Presents Data from Ongoing Phase 1/2 Trial of AGTC-501 at Upcoming American Academy of Ophthalmology 2021 Annual MeetingGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the tre
5y agoAGTCAGTC Appoints Hope D'Oyley-Gay as General CounselGlobeNewswireMs. D'Oyley-Gay brings significant legal experience as well as business development and commercial operations expertise from both biotech and pharmaceutical companies GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Applie
5y agoAGTC OTICOtonomy Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireOTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022 Enrollment nearly complete in OTO-413 Phase 2a cohort in hearing loss with results moved forward to early in second quarter of 2022 Initiating clinical safety evaluation of hi
5y agoAGTCAGTC to Participate in the Stifel 2021 Virtual Healthcare ConferenceGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the trea
5y agoAGTCAGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2021GlobeNewswire-Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022- -Company to host management update and webcast today at 8:00 a.m. ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE N
5y agoAGTCAGTC to Host First Quarter Financial Results Conference Call and Webcast on November 9, 2021GlobeNewswireGAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the tre
5y agoAGTCAGTC to Present at Upcoming Dry AMD Therapeutic Development SummitGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the tre
5y agoAGTCAGTC Announces Two Key Leadership Team AppointmentsGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the tre
5y agoAGTCAGTC to Present at Upcoming Cell & Gene Management Meeting on the MesaGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the tr
5y agoAGTCAGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal DegenerationGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the t
5y agoAGTCAGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare ConferenceGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the tre
5y agoAGTCAGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021GlobeNewswire-Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022- -Pre-Clinical programs moving to IND enabling animal studies- -Company adds experienced indu
5y agoAGTCAGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021GlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the tre
5y agoAGTCAGTC to Participate in Clinical Trials in Rare Diseases Conference Panel and Case StudyGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the t
5y agoAGTCAGTC is Excited to Announce Seasoned Healthcare Financial and Operations Executive Jonathan I. Lieber as their new Chief Financial OfficerGlobeNewswireGAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the